With a market capitalization (market cap) of $2.7B — a measure of how much the company is worth — AxoGen, Inc. is the 1899th most valuable company in Healthcare as of August 19, 2026. Shares trade at $50.19, up +2.12% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Visit websiteAs of August 19, 2026, AxoGen, Inc. (AXGN) is worth $2.7B — this is its market capitalization, the total value of all its outstanding shares.
AxoGen, Inc.’s market cap is $2.7B, which ranks it #1899 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
AxoGen, Inc. (AXGN) shares trade at $50.19, up 2.12% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025